Skip to content
10-Q

Quarterly Report

Arcus Biosciences, Inc. RCUS

0001724521-25-000116

← back to feed
Filed
Oct 28, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 23, 2025 107.97M sh
Shares Diluted Q3 2025 · Sep 30, 2025 106.5M sh
Shares Diluted Q3 2025 · Sep 30, 2025 103.7M sh
Shares Diluted Q3 2025 · Sep 30, 2024 91.4M sh
Shares Diluted Q3 2025 · Sep 30, 2024 89.6M sh
Capex Q3 2025 · Sep 30, 2025 $1M
Capex Q3 2025 · Sep 30, 2024 $5M
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$362M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$70M
Long Term Debt Q3 2025 · Sep 30, 2025 $98M
Long Term Debt Q3 2025 · Dec 31, 2024 $48M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $238M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $150M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $201M
Stockholders Equity Q3 2025 · Sep 30, 2025 $436M
Stockholders Equity Q3 2025 · Jun 30, 2025 $549M
Stockholders Equity Q3 2025 · Mar 31, 2025 $531M
Stockholders Equity Q3 2025 · Dec 31, 2024 $485M
Stockholders Equity Q3 2025 · Sep 30, 2024 $565M
Stockholders Equity Q3 2025 · Jun 30, 2024 $635M
Stockholders Equity Q3 2025 · Mar 31, 2024 $707M
Stockholders Equity Q3 2025 · Dec 31, 2023 $462M
Current Liabilities Q3 2025 · Sep 30, 2025 $235M
Current Liabilities Q3 2025 · Dec 31, 2024 $226M
Current Assets Q3 2025 · Sep 30, 2025 $857M
Current Assets Q3 2025 · Dec 31, 2024 $1.02B
Total Assets Q3 2025 · Sep 30, 2025 $974M
Total Assets Q3 2025 · Dec 31, 2024 $1.15B
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.27
Eps Diluted Q3 2025 · Sep 30, 2025 −$2.39
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.00
Eps Diluted Q3 2025 · Sep 30, 2024 −$2.11
Eps Basic Q3 2025 · Sep 30, 2025 −$1.27
Eps Basic Q3 2025 · Sep 30, 2025 −$2.39
Eps Basic Q3 2025 · Sep 30, 2024 −$1.00
Eps Basic Q3 2025 · Sep 30, 2024 −$2.11
Sga Expense Q3 2025 · Sep 30, 2025 $27M
Sga Expense Q3 2025 · Sep 30, 2025 $84M
Sga Expense Q3 2025 · Sep 30, 2024 $30M
Sga Expense Q3 2025 · Sep 30, 2024 $92M
Rd Expense Q3 2025 · Sep 30, 2025 $141M
Rd Expense Q3 2025 · Sep 30, 2025 $402M
Rd Expense Q3 2025 · Sep 30, 2024 $123M
Rd Expense Q3 2025 · Sep 30, 2024 $347M
Net Income Q3 2025 · Sep 30, 2025 −$135M
Net Income Q3 2025 · Sep 30, 2025 −$247M
Net Income Q3 2025 · Jun 30, 2025 $0
Net Income Q3 2025 · Mar 31, 2025 −$112M
Net Income Q3 2025 · Sep 30, 2024 −$92M
Net Income Q3 2025 · Sep 30, 2024 −$189M
Net Income Q3 2025 · Jun 30, 2024 −$93M
Net Income Q3 2025 · Mar 31, 2024 −$4M
Operating Income Q3 2025 · Sep 30, 2025 −$142M
Operating Income Q3 2025 · Sep 30, 2025 −$272M
Operating Income Q3 2025 · Sep 30, 2024 −$105M
Operating Income Q3 2025 · Sep 30, 2024 −$227M
Revenue Q3 2025 · Sep 30, 2025 $6M
Revenue Q3 2025 · Sep 30, 2025 $22M
Revenue restated Q3 2025 · Sep 30, 2024 $7M
Revenue restated Q3 2025 · Sep 30, 2024 $28M